Here are five things to know about the transaction and the company’s stock:
• The shares were sold at an average price of $44.82, for a total value of $238,128.
• Mr. Lukianov now directly owns 328,367 shares of the company’s stock, valued at approximately $14.7 million.
• NuVasive currently has an average rating of “buy” and a consensus price target of $52.27.
• The company has a one-year low of $31.35 and a one-year high of $51.23.
• NuVasive’s market cap is $2.136 billion.
More articles on devices:
FDA approves Tornier’s shoulder system, aims to improve shoulder arthroplasty — 4 things to know
Piper Jaffray assumes Integra LifeSciences coverage — 5 things to know
Zimmer sells $7.65B of senior notes for Biomet merger — 7 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
